BOSTON, Feb. 17 /PRNewswire-FirstCall/ -- PAREXEL Consulting, a business unit of PAREXEL International and leading global consultancy serving the biopharmaceutical and medical device industries, has appointed Anders Neil, Ph.D., to the position of Principal Consultant in its European Product Development Practice. Dr. Neil, former Senior Expert, Pharmacology and Toxicology, at Sweden’s Medical Products Agency (MPA), will advise clients on all aspects of clinical development and regulatory affairs. He joins the PAREXEL Consulting team of global experts, which includes former regulatory officials and biopharmaceutical industry professionals, focused on helping companies manage risk and maximize product and portfolio value at every milestone and during each phase of development.
With more than 20 years of experience, Mr. Neil’s background includes pharmacology research, drug discovery, and drug development. Prior to working at the MPA, Dr. Neil’s career included more than 10 years in the pharmaceutical industry, serving as Principal Scientist at Biovitrum AB as well as Group Manager, Pharmacology at Kabi-Pharmacia/Pharmacia & Upjohn.
“We expect clients will benefit greatly from the insight Dr. Neil has gained from helping to shape regulatory policies in Europe,” said Peter Lassoff, Pharm D, Vice President, Europe, PAREXEL Consulting. “Dr. Neil’s scientific advice and extensive regulatory and clinical experience will be invaluable in many areas, including in understanding new pediatric requirements as well as applying proactive safety strategies and risk management methodologies. He also brings a wealth of expertise in regard to product development in Sweden, which is the fourth largest biopharmaceutical market in Europe, to supplement our industry leading capabilities in Scandinavia.”
“PAREXEL’s consulting experts are recognized for managing successful interactions with regulatory agencies, delivering world-class submissions, and helping biopharmaceutical companies define and execute the most efficient paths to approval,” said Dr. Neil. “I am proud to join such a high caliber team of experts to help clients with scientific decisions, especially early in development planning, and with regulatory approaches to achieve first-cycle approval.”
Dr. Neil was appointed as Senior Expert by MPA in 2005, following his long-term role as MPA Team Leader. During his tenure at MPA Dr. Neil assessed marketing authorizations and clinical trial applications, including nonclinical and pharmacology aspects of more than 1,000 applications spanning all stages of development and therapeutic areas. He has served as an expert to the European Committee for Proprietary Medicinal Products (CPMP), now the Committee for Medicinal Products for Human Use (CHMP), and to its Safety Working Party as a rapporteur on European Union (EU) regulatory documents. Dr. Neil was also appointed to the EU Commission’s list of scientific experts on emerging and newly identified health risks. Dr. Neil is currently an Associate Professor of Pharmacology at Uppsala University in Sweden.
For more information about PAREXEL Consulting’s full capabilities and areas of expertise, visit: http://www.parexelconsulting.com.
About PAREXEL Consulting
PAREXEL Consulting, a division of PAREXEL International, provides integrated product development services with the goal of helping biopharmaceutical and medical device companies get their products to the market, and keep them on the market. Through a unique fusion of scientific, regulatory, and business expertise PAREXEL Consulting helps clients worldwide manage risk and maximize product and portfolio value at every milestone and during each phase of development.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International Corporation, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or
Rebecca Passo of SHIFT Communications, +1-617-779-1817,
rpasso@shiftcomm.com, for PAREXEL International Corporation
Web site: http://www.PAREXEL.com/
